Johannes Gutenberg-Universität Mainz
- 6131/39-0
Brabec, Tomas; Vobonl, Matous; Schierova, Dagmar et al.
IL-17-driven induction of Paneth cell antimicrobial functions protects the host from microbiota dysbiosis and inflammation in the ileumMUCOSAL IMMUNOLOGY. Bd. 16. H. 4. 2023 S. 373-385
Fischer, Berenice; Kuebelbeck, Tanja; Kolb, Antonia et al.
IL-17A-driven psoriasis is critically dependent on IL-36 signalingFRONTIERS IN IMMUNOLOGY. Bd. 14. 2023
Picard, Felix Simon Ruben; Lutz, Veronika; Brichkina, Anna et al.
IL-17A-producing CD8(+) T cells promote PDAC via induction of inflammatory cancer-associated fibroblastsGUT. 2023
Guedes, Joana R.; Ferreira, Pedro A.; Costa, Jessica et al.
IL-4 shapes microglia-dependent pruning of the cerebellum during postnatal developmentNEURON. Bd. 111. H. 21. 2023 S. 3435-3449
Lutz, Veronika; Hellmund, Veronique M.; Picard, Felix S. R. et al.
IL18 Receptor Signaling Regulates Tumor-Reactive CD8<SUP>+</SUP> T-cell Exhaustion via Activation of the IL2/STAT5/mTOR Pathway in a Pancreatic Cancer ModelCANCER IMMUNOLOGY RESEARCH. Bd. 11. H. 4. 2023 S. 421-434
Stoehr, Fabian; Mildenberger, Peter; Jorg, Tobias
Image interpretation and the radiological reportRADIOLOGIE. Bd. 63. H. 2. 2023 S. 110-114
Marciniak, Marta Anna; Shanahan, Lilly; Myin-Germeys, Inez et al.
Imager-A mobile health mental imagery-based ecological momentary intervention targeting reward sensitivity: A randomized controlled trialAPPLIED PSYCHOLOGY-HEALTH AND WELL BEING. 2023
Sala, Arianna; Herfert, Kristina; Gonzalez-Escamilla, Gabriel et al.
Imaging brain molecular connectivity in health and diseaseFRONTIERS IN HUMAN NEUROSCIENCE. Bd. 17. 2023
Kudo, Masatoshi; Finn, Richard S. S.; Galle, Peter R. R. et al.
IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma-An Exploratory Analysis of the Phase III StudyLIVER CANCER. Bd. 12. H. 3. 2023 S. 238-250
Kudo, Masatoshi; Tsuchiya, Kaoru; Shao, Yu Yun et al.
IMbrave150: Exploratory analysis to examine the association between bevacizumab (bev) ever being skipped and bev never being skipped in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) plus bev in a global phase 3 study.JOURNAL OF CLINICAL ONCOLOGY. Bd. 41. 2023 S. 538-538